儿童低级别胶质瘤的分子标志物与靶向治疗
本文综述儿童低级别胶质瘤中常见的分子改变及其在诊断、预后和治疗中的作用,并总结MEK和BRAF抑制剂相关临床试验的疗效数据。靶向MAPK通路的治疗为肿瘤控制提供了新机制,但仍有诸多未解问题。
要点
- 儿童低级别胶质瘤的分子改变有助于细化肿瘤分类。
- MAPK通路靶向治疗(MEK/BRAF抑制剂)是正在研究的新策略。
- 分子标志物与组织病理学结合可提供诊断和预后新见解。
核心结论
- 儿童低级别胶质瘤驱动性分子改变的识别及靶向治疗的发展为患者开辟了新的治疗途径。
研究设计与样本
- 本文为专题综述,回顾了儿童低级别胶质瘤中常见的分子改变以及MEK和BRAF抑制剂的近期临床试验。
主要发现
- 新发现的分子改变有助于细化儿童低级别胶质瘤的分类。
- 遗传学异常可与组织病理学结合,为胶质瘤分类、发生和预后提供新见解。
- 靶向MAPK通路常见遗传学异常的治疗提供了新的肿瘤控制机制,目前正在研究中。
临床怎么用
- 临床可关注儿童低级别胶质瘤的分子分型,并了解MAPK通路靶向治疗的研究进展。
局限性
- 本文未报告靶向治疗的具体疗效数值及未解问题的详细清单。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Recently discovered molecular alterations in pediatric low-grade glioma have helped to refine the classification of these tumors and offered novel targets for therapy. Genetic aberrations may combine with histopathology to offer new insights into glioma classification, gliomagenesis and prognosis. Therapies targeting common genetic aberrations in the MAPK pathway offer a novel mechanism of tumor control that is currently under study. METHODS: We have reviewed common molecular alterations found in pediatric low-grade glioma as well as recent clinical trials of MEK and BRAF inhibitors. RESULTS: In this topic review, we examine the current understanding of molecular alterations in pediatric low-grade glioma, as well as their role in diagnosis, prognosis and therapy. We summarize current data on the efficacy of targeted therapies in pediatric low-grade gliomas, as well as the many unanswered questions that these new discoveries and therapies raise. CONCLUSIONS: The identification of driver alterations in pediatric low-grade glioma and the development of targeted therapies have opened new therapeutic avenues for patients with low-grade gliomas.
引用
- de Blank P, Fouladi M, Huse JT, et al. Molecular markers and targeted therapy in pediatric low-grade glioma. J Neurooncol. 2020. PMID: 32399739. doi:10.1007/s11060-020-03529-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。